San Francisco, United States
Tamarind Bio, founded in 2023, is an innovative startup headquartered in the United States, operating at the intersection of AI, SaaS, and Machine Learning. Their core offering, an AI Platform for Computational Molecular Design, empowers users with web interfaces and APIs that streamline access to over 200 molecular design models. The platform’s ability to process thousands of inputs in parallel distinguishes it as a key player in bioinformatics.
Their clientele includes numerous top-tier biopharma companies that leverage the platform to design novel binders, optimize protein binders, and assess antigen attributes. This functionality resonates with industries focused on advanced molecular and protein engineering, enhancing both research efficiency and innovation.
In February 2026, Tamarind Bio secured a $13.60M Series A investment from Dimension Capital, underlining significant investor confidence in their potential to disrupt molecular design processes. This strategic backing spotlights their growth trajectory and potential for future scalability.
